Stephan Schwers

1.6k total citations
30 papers, 1.2k citations indexed

About

Stephan Schwers is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Stephan Schwers has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 8 papers in Genetics and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Stephan Schwers's work include Blood Coagulation and Thrombosis Mechanisms (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Stephan Schwers is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Stephan Schwers collaborates with scholars based in Germany, United States and Netherlands. Stephan Schwers's co-authors include Klaus Rajewsky, Eiichiro Sonoda, Jan Stampfuss, Wolfgang Mueck, Raul M. Torres, David Nemazee, Roberta Pelanda, Yael Pewzner‐Jung, Shinsuke Taki and Steffen Jung and has published in prestigious journals such as Nature, Blood and Immunity.

In The Last Decade

Stephan Schwers

29 papers receiving 1.2k citations

Peers

Stephan Schwers

IMMUN

CCM

HEMAT

GENET

Maurice Redondo Switzerland

Pradip K. Rustagi United States

Ole Nordfang Denmark

Antonia Miñano Spain

J Niemetz United States

Mohamed Hatmi France

ML Rand Canada

Cristiana Bulato Italy

Karin Müller Germany

Yoshitaka Hosaka Japan

Maurice Redondo Switzerland

Stephan Schwers

194 ×0.4

IMMUN

275 ×0.7

CCM

438 ×1.6

HEMAT

107 ×0.4

286 ×1.4

GENET

Citations per year, relative to Stephan Schwers Stephan Schwers (= 1×) peers Maurice Redondo

Countries citing papers authored by Stephan Schwers

Since Specialization

Citations

This map shows the geographic impact of Stephan Schwers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Schwers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Schwers more than expected).

Fields of papers citing papers by Stephan Schwers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Schwers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Schwers. The network helps show where Stephan Schwers may publish in the future.

Co-authorship network of co-authors of Stephan Schwers

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Schwers. A scholar is included among the top collaborators of Stephan Schwers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Schwers. Stephan Schwers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Huijun, Kirstin Thelen, Frauke Friedrichs, et al.. (2024). Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and Translational Science. 17(4). e13784–e13784. 7 indexed citations

Schiffer, Sonja, Stephan Schwers, & Stefan Heitmeier. (2023). The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence. Journal of Thrombosis and Thrombolysis. 55(3). 449–463. 4 indexed citations

Nagy, Magdolna, Mayken Visser, Thomas Koeck, et al.. (2023). Predictive value for increased activated factor XI activity in acute venous thromboembolism. Journal of Thrombosis and Haemostasis. 21(6). 1610–1622. 10 indexed citations

Kubitza, Dagmar, et al.. (2022). Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study. British Journal of Clinical Pharmacology. 88(7). 3447–3462. 43 indexed citations

Cate, Vincent ten, Andreas Schulz, Jürgen H. Prochaska, et al.. (2022). Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis. Scientific Reports. 12(1). 9761–9761. 26 indexed citations

Nowotny, Bettina, et al.. (2022). First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men. Journal of Thrombosis and Haemostasis. 20(7). 1684–1695. 19 indexed citations

Binder, Nikolaus B., et al.. (2021). Clinical use of thrombin generation assays. Journal of Thrombosis and Haemostasis. 19(12). 2918–2929. 69 indexed citations

Thomas, Dirk, et al.. (2021). First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. Journal of Thrombosis and Haemostasis. 19(10). 2407–2416. 59 indexed citations

Thomas, Dirk, Kirstin Thelen, Stefanie Kraff, et al.. (2019). BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics. Research and Practice in Thrombosis and Haemostasis. 3(2). 242–253. 58 indexed citations

10.

Kreutz, Reinhold, Pontus B. Persson, Dagmar Kubitza, et al.. (2017). Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study. Journal of Thrombosis and Haemostasis. 15(10). 2017–2028. 38 indexed citations

11.

Watz, Henrik, Johannes Nagelschmitz, Frauke Pedersen, et al.. (2014). Conduct of a biomarker study in bronchiectasis patients: Correlation of neutrophil elastase activity and inflammatory load in induced sputum. European Respiratory Journal. 44(Suppl 58). P2049–P2049. 2 indexed citations

12.

Nagelschmitz, Johannes, et al.. (2014). The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations. European Respiratory Journal. 44(Suppl 58). P1511–P1511. 2 indexed citations

13.

Nagelschmitz, Johannes, Stephan Schwers, Franz von Nussbaum, et al.. (2014). The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases. European Respiratory Journal. 44(Suppl 58). 3416–3416. 5 indexed citations

14.

Nagelschmitz, Johannes, et al.. (2014). The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects. European Respiratory Journal. 44(Suppl 58). P1510–P1510. 2 indexed citations

15.

Kubitza, Dagmar, Michael Becka, Stephan Schwers, & Barbara Voith. (2013). Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clinical Pharmacology in Drug Development. 2(3). 270–277. 25 indexed citations

16.

Mueck, Wolfgang, Stephan Schwers, & Jan Stampfuss. (2013). Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thrombosis Journal. 11(1). 10–10. 129 indexed citations

17.

Rohde, Gabriele, Gertrud Stratmann, Christian W. Hesse, et al.. (2012). Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thrombosis and Haemostasis. 108(7). 191–198. 82 indexed citations

18.

Qin, F. Xiao‐Feng, Stephan Schwers, Wong Yu, et al.. (1999). Secondary V(D)J recombination in B-1 cells. Nature. 397(6717). 355–359. 62 indexed citations

19.

Sonoda, Eiichiro, Yael Pewzner‐Jung, Stephan Schwers, et al.. (1997). B Cell Development under the Condition of Allelic Inclusion. Immunity. 6(3). 225–233. 202 indexed citations

20.

Pelanda, Roberta, Stephan Schwers, Eiichiro Sonoda, et al.. (1997). Receptor Editing in a Transgenic Mouse Model: Site, Efficiency, and Role in B Cell Tolerance and Antibody Diversification. Immunity. 7(6). 765–775. 235 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact